 |
July 4th, 2002, 11:13
|
|
Administrator
|
|
Join Date: 2001
Posts: 1,085
|
|
|
June 2002
Thursday, June 20, 2002
Syndrome X Chest Pain Associated With Subendocardial HypoperfusionThis MRI study of 20 patients with syndrome X (typical angina, abnormal exercise ECG test results, and normal coronary angiogram) and 10 control patients, subendocardial hypoperfusion was demonstrated after adenosine stress. This suggests that the chest pain in syndrome X is due to myocardial ischemia. [ article ] posted at 7:31 AM
Monday, June 17, 2002
Disagreement Over the Meaning of HOPE: the Use of Ramipril to Prevent Cardiovascular EventsLetters to the editor published in Lancet raise interesting points about the HOPE trial, which showed a significant benefit of adding ramipril to other blood pressure medications. The main authors of the HOPE trial respond convincingly. Comment: this is interesting reading. I tend to side with the authors of the HOPE trial, and believe that ramipril is a promising medication in terms of cardiovascular disease treatment and prevention. [ article ] posted at 10:58 AM
Friday, June 14, 2002
Dual Chamber Pacing Best for Sinus Node DysfunctionThis study of 2010 patients with sinus node dysfunction found that dual chamber pacing (atrioventricular) was better than single chamber (ventricular only) pacing. There was no difference between the two groups in terms of mortality or stroke-free survival, however, those with dual chamber pacemakers had fewer signs and symptoms of heart failure, and an improved quality of life. [ article ] posted at 2:07 PM
Raloxifene Shown to Reduce Strokes and Coronary EventsResearch presented at the annual meeting of the American College of Cardiology reported that among the 1035 participants in the MORE trial, those who took 60 mg/day of raloxifene (an alternative to hormone replacement therapy) had a 40% reduction in coronary events compared with those taking a placebo. The reduction in strokes was 62%. Comment: this selective estrogen receptor modulator is very promising, and likely will be the preferred post-menopausal agent, replacing estrogen. [ Family Practice News 15 May 2002;32(10):1 ] posted at 1:32 PM
Thursday, June 13, 2002
Therapeutic Angiogenesis Shows Potential for Treating Vascular DiseaseThis study of 190 patients with intermittent claudication in their legs showed a good response to the intra-arterial infusion of recombinant fibroblast growth factor-2. Comment: this growth factor may eventually help cardiac patients grow collateral vessels, decreasing the need for repeat stenting or bypass surgery. [ article ] posted at 10:53 PM
|
| Thread Tools |
Search this Thread |
|
|
|
| Display Modes |
 Linear Mode
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is On
|
|
|
All times are GMT -8. The time now is 21:48.
|
